共 140 条
[1]
Mottet N(2017)EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent Eur Urol 71 618-629
[2]
Bellmunt J(2016)The rise of PSMA ligands for diagnosis and therapy of prostate cancer J Nucl Med 57 79s-89s
[3]
Bolla M(2018)Reproducibility of standardized uptake values of same-day randomized (68)Ga-PSMA-11 PET/CT and PET/MR scans in recurrent prostate cancer patients Ann Nucl Med 32 523-531
[4]
Briers E(2017)Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy J Med Radiat Sci 64 52-60
[5]
Cumberbatch MG(2016)New strategies in prostate cancer: prostate-specific membrane Antigen (PSMA) ligands for diagnosis and therapy Clin Cancer Res 22 9-15
[6]
De Santis M(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
[7]
Afshar-Oromieh A(2009)From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 122s-150s
[8]
Babich JW(2016)Practical PERCIST: a simplified guide to PET response criteria in solid tumors 10 Radiology 280 576-584
[9]
Kratochwil C(2016)Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review Oncotarget 7 58105-58110
[10]
Giesel FL(2017)Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments Eur J Nucl Med Mol Imaging 44 55-66